Good MorningEquities slipped again on Wednesday with the FOMC’s Beige Book in the market’s focus. The Beige Book revealed improving conditions but also a growing uncertainty spurred by the resurgence of COVID-19 as well as mounting inflation. The key takeaway from the report is that the FOMC is still on track to begin tapering sometime this year.
The market may get another clue as to when that will happen on Friday with the release of the PPI data. The consensus is for producer price increases to moderate from a 1.0% monthly gain posted in August to a slower 0.6% gain in September. Even so, producer level inflation is rising quickly and will lead to higher consumer prices down the road. If the PPI comes in hotter than expected the FOMC could begin the taper as soon as the September meeting in two weeks’ time.
Featured: Gold Is About to Do Something It Hasn’t in 90 Years (Ad) 
|
Consumer Staples | | The concept of passive income is certainly attractive on paper, as it involves generating regular money flows with minimal activity. However, creating a reliable passive income source is easier said than done. Some people look to business activities or real estate rental income to generate steady st... Read the Full Story |
|
From Our Partners | | The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance estimates it could unlock $400 trillion - but analyst Jeff Brown, who was consulted by Congressional offices on the legislation, believes the real figure could reach $2.6 quadrillion.
Brown says this shift will pour onto a new type of investment exchange - and he's showing investors how to position themselves starting with just $100. | | Click here to see how Jeff Brown says to claim your stake |
|
Retail/Wholesale | |
If you happened to hold Kirkland’s (NASDAQ: KIRK) stock throughout all of last year, you enjoyed a mind-blowing 1,342% return. The home décor retailer was among the top 10 U.S. stock performers in 2020 thanks to pandemic-driven shopping habits and Kirkland’s strengthened competi... Read the Full Story |
|
Markets | |
Index funds are a curious thing.
On the one hand, plenty of long-term investors swear by them as a way of automating retirement investing and creating an allocated portfolio.
On the other hand, some investors correctly point out that an over-reliance on index funds can limit other investment o... Read the Full Story |
|
From Our Partners | | OpenAI and Anthropic are moving closer to the public-market spotlight - and Wall Street rarely waits until the first trading day to reposition.
By the time these IPOs arrive, the obvious AI names may already be crowded and fully priced. The earlier opportunity could lie in chips, cloud infrastructure, data tools, and enterprise AI systems. One report covers 9 AI stocks - including a chip name tied to U.S. infrastructure, a cloud player with an underappreciated setup, and a data analytics business with government and enterprise exposure. | | Review the full 9-stock AI breakdown before the next wave hits |
|
Business Services | | Baby monitor and products maker Owlet (NYSE: OWLT) stock has been pummeled so far in 2021. Most recently shares collapsed over (-20%) to all-time lows on new that the SEC has allowed warrant holders to exercise their options. This could lead to an additional 18.1 million shares to be issued on top o... Read the Full Story |
|
Consumer Discretionary | |
For some traditional investors, it may be easy to dismiss the retail trading community on Reddit. One reason for this is that many Reddit investors use the trading app Robinhood (NASDAQ: HOOD), which is widely seen as a catalyst for the rise in “meme stocks” such as GameStop and AMC En... Read the Full Story |
|
From Our Partners | | The government just committed $200 billion to building computer chips on American soil - one of the largest technology bets in U.S. history.
George Gilder, who has tracked technology signals for over 40 years, believes Washington just tipped its hand. He says this move points to a coming shift in computing that could leave today's machines behind - and most investors have already moved past the headline. | | See the signal George Gilder is reading before the market catches on |
|
Markets | |
Invest In Cloud Stocks With True Utility
The cloud has long been a driving force of growth within the tech industry and it will remain so long into the future. The problem for investors, if there is one, is that the growth of the cloud has slowed which makes cloud services and cloud-based busines... Read the Full Story |
|
Medical | | It’s been a relatively quiet week for IPOs, but as summer transitions into fall, look for that to change.
According to IPO tracker Renaissance Capital, as many as 15 companies may join the public markets in the coming week. These include eyeglass retailer Warby Parker, tech consulting firm T... Read the Full Story |
|
Auto/Tires/Trucks | |
The transition to electric vehicles may take longer than breathlessly imagined at the end of 2020, but it is occurring. The Biden administration still is shooting for an aggressive target. Specifically by 2030, the administration wants 50% of the vehicles sold in the United States to be either bat... Read the Full Story |
|
Finance | | Insurance fintech platform provider Lemonade (NYSE: LMND) stock is turning the corner after recovering from Q1 2021 Texas Freeze. The fintech provides insurance products for home, life, rental, pets, and soon-to-be car. The car insurance is a strong tailwind for the Company as it completed the devel... Read the Full Story |
|
Technology | |
In the week after CrowdStrike Holdings (NASDAQ: CRWD) reported earnings, CRWD stock is down nearly 6% (5.8%). The earnings report was strong with CrowdStrike beating on both earnings and revenue.
Since debuting in June 2019, the stock is up 320%. However, investors have long been concerned abou... Read the Full Story |
|
The Early Bird Stock Of The Day Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China. | | View Today's Stock Pick |
|
